Sangamo Therapeutics Inc (NASDAQ: SGMO) rose 7.4% to $4.35 after the company reported the presentation of new data showing “significant reduction of tau mRNA, tau protein expression using ZFP-TF-mediated gene regulation technology.” Share volume was 597,000, compared to an all-day average of 683,000
